EV/Sales Ratio: 3.83x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 3.83x is 30% below its 5-year average of 5.44x, near the low end of its 5-year range (2.08x–10.10x).
As of Saturday, June 27, 2026. 20.99% above its 12-month average of 3.17x.
NRC EV/Sales Ratio Chart
NRC Average EV/Sales Ratio Chart
NRC Current vs Average EV/Sales Ratio Chart
NRC EV/Sales Ratio Metrics
EV/SALES RATIO
3.83x
EV/SALES RATIO AVG TTM
3.17x
EV/SALES RATIO AVG 3Y
4.35x
EV/SALES RATIO AVG 5Y
5.44x
EV/SALES RATIO AVG 10Y
6.97x
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+20.99%
CURRENT VS 3Y AVG
-12.05%
CURRENT VS 5Y AVG
-29.61%
CURRENT VS 10Y AVG
-45.02%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NRC Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| National Research Corporation (NRC) | $468.99M | 3.83x | 3.17x | 4.35x | 5.44x |
| Shoulder Innovations, Inc. (SI)vs › | $472.62M | 8.80x | 6.44x | 6.44x | 6.44x |
| 23andMe Holding Co. (ME)vs › | $15.31M | 0.02x | 0.35x | 0.71x | 3.53x |
| Teladoc Health, Inc. (TDOC)vs › | $1.51B | 0.71x | 0.61x | 0.91x | 2.86x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.21B | 1.18x | 1.26x | 1.70x | 2.15x |
| TransMedics Group, Inc. (TMDX)vs › | $2.37B | 4.53x | 8.47x | 11.09x | 16.19x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.56B | 3.54x | 4.57x | 4.21x | 4.22x |
| Oscar Health, Inc. (OSCR)vs › | $7.72B | 0.41x | 0.23x | 0.31x | 0.44x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.13B | 3.47x | 3.43x | 3.66x | 4.54x |
| Universal Health Services, Inc. (UHS)vs › | $9.12B | 0.79x | 1.03x | 1.12x | 1.13x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for National Research Corporation (NRC)?
- The EV/Sales ratio for NRC stock is 3.83x.
- Is National Research Corporation's EV/Sales ratio high or low?
- The EV/Sales ratio of 3.83x is 30% below its 5-year average of 5.44x, near the low end of its 5-year range (2.08x–10.10x).
- What is the TTM average EV/Sales ratio for National Research Corporation (NRC)?
- The TTM average EV/Sales ratio for NRC stock is 3.17x.
- What is the 3Y average EV/Sales ratio for National Research Corporation (NRC)?
- The 3Y average EV/Sales ratio for NRC stock is 4.35x.
- What is the 5Y average EV/Sales ratio for National Research Corporation (NRC)?
- The 5Y average EV/Sales ratio for NRC stock is 5.44x.
- What is the 10Y average EV/Sales ratio for National Research Corporation (NRC)?
- The 10Y average EV/Sales ratio for NRC stock is 6.97x.
NRC EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-26 | 3.83x |
| 2026-06-25 | 3.79x |
| 2026-06-24 | 3.82x |
| 2026-06-23 | 3.71x |
| 2026-06-22 | 3.62x |
| 2026-06-18 | 3.47x |
| 2026-06-17 | 3.35x |
| 2026-06-16 | 3.46x |
| 2026-06-15 | 3.44x |
| 2026-06-12 | 3.51x |
| 2026-06-11 | 3.51x |
| 2026-06-10 | 3.91x |
| 2026-06-09 | 3.67x |
| 2026-06-08 | 3.60x |
| 2026-06-05 | 3.57x |
| 2026-06-04 | 3.67x |
| 2026-06-03 | 3.55x |
| 2026-06-02 | 3.64x |
| 2026-06-01 | 3.74x |
| 2026-05-29 | 3.63x |
| 2026-05-28 | 3.65x |
| 2026-05-27 | 3.57x |
| 2026-05-26 | 3.55x |
| 2026-05-22 | 3.56x |
| 2026-05-21 | 3.55x |
| 2026-05-20 | 3.59x |
| 2026-05-19 | 3.51x |
| 2026-05-18 | 3.51x |
| 2026-05-15 | 3.49x |
| 2026-05-14 | 3.54x |
| 2026-05-13 | 3.50x |
| 2026-05-12 | 3.58x |
| 2026-05-11 | 3.50x |
| 2026-05-08 | 3.51x |
| 2026-05-07 | 3.50x |
| 2026-05-06 | 3.37x |
| 2026-05-05 | 3.52x |
| 2026-05-04 | 3.44x |
| 2026-05-01 | 3.31x |
| 2026-04-30 | 3.16x |
| 2026-04-29 | 3.17x |
| 2026-04-28 | 3.22x |
| 2026-04-27 | 3.26x |
| 2026-04-24 | 3.28x |
| 2026-04-23 | 3.28x |
| 2026-04-22 | 3.32x |
| 2026-04-21 | 3.27x |
| 2026-04-20 | 3.43x |
| 2026-04-17 | 3.41x |
| 2026-04-16 | 3.34x |
| 2026-04-15 | 3.38x |
| 2026-04-14 | 3.25x |
| 2026-04-13 | 3.21x |
| 2026-04-10 | 3.16x |
| 2026-04-09 | 3.25x |
| 2026-04-08 | 3.28x |
| 2026-04-07 | 3.25x |
| 2026-04-06 | 3.30x |
| 2026-04-02 | 3.27x |
| 2026-04-01 | 3.30x |
| 2026-03-31 | 3.24x |
| 2026-03-30 | 3.27x |
| 2026-03-27 | 3.26x |
| 2026-03-26 | 3.33x |
| 2026-03-25 | 3.27x |
| 2026-03-24 | 3.31x |
| 2026-03-23 | 3.32x |
| 2026-03-20 | 3.29x |
| 2026-03-19 | 3.29x |
| 2026-03-18 | 3.33x |
| 2026-03-17 | 3.36x |
| 2026-03-16 | 3.31x |
| 2026-03-13 | 3.17x |
| 2026-03-12 | 3.16x |
| 2026-03-11 | 3.09x |
| 2026-03-10 | 3.13x |
| 2026-03-09 | 2.92x |
| 2026-03-06 | 2.86x |
| 2026-03-05 | 2.77x |
| 2026-03-04 | 2.69x |
| 2026-03-03 | 2.73x |
| 2026-03-02 | 2.81x |
| 2026-02-27 | 2.74x |
| 2026-02-26 | 2.74x |
| 2026-02-25 | 2.66x |
| 2026-02-24 | 2.59x |
| 2026-02-23 | 2.59x |
| 2026-02-20 | 2.78x |
| 2026-02-19 | 2.58x |
| 2026-02-18 | 2.56x |
| 2026-02-17 | 2.51x |
| 2026-02-13 | 2.52x |
| 2026-02-12 | 2.64x |
| 2026-02-11 | 2.79x |
| 2026-02-10 | 2.92x |
| 2026-02-09 | 3.06x |
| 2026-02-06 | 3.15x |
| 2026-02-05 | 3.15x |
| 2026-02-04 | 3.04x |
| 2026-02-03 | 3.42x |
| 2026-02-02 | 4.12x |
| 2026-01-30 | 3.86x |
| 2026-01-29 | 3.82x |
| 2026-01-28 | 3.78x |
| 2026-01-27 | 3.86x |
| 2026-01-26 | 3.94x |
| 2026-01-23 | 3.98x |
| 2026-01-22 | 4.13x |
| 2026-01-21 | 4.21x |
| 2026-01-20 | 4.11x |
| 2026-01-16 | 4.17x |
| 2026-01-15 | 4.02x |
| 2026-01-14 | 3.94x |
| 2026-01-13 | 3.95x |
| 2026-01-12 | 3.88x |
| 2026-01-09 | 3.76x |
| 2026-01-08 | 3.72x |
| 2026-01-07 | 3.63x |
| 2026-01-06 | 3.69x |
| 2026-01-05 | 3.61x |
| 2026-01-02 | 3.49x |
| 2025-12-31 | 3.61x |
| 2025-12-30 | 3.59x |
| 2025-12-29 | 3.64x |
| 2025-12-26 | 3.59x |
| 2025-12-24 | 3.61x |
| 2025-12-23 | 3.65x |
| 2025-12-22 | 3.63x |
| 2025-12-19 | 3.60x |
| 2025-12-18 | 3.69x |
| 2025-12-17 | 3.59x |
| 2025-12-16 | 3.55x |
| 2025-12-15 | 3.48x |
| 2025-12-12 | 3.42x |
| 2025-12-11 | 3.39x |
| 2025-12-10 | 3.31x |
| 2025-12-09 | 3.16x |
| 2025-12-08 | 3.13x |
| 2025-12-05 | 3.14x |
| 2025-12-04 | 3.21x |
| 2025-12-03 | 3.19x |
| 2025-12-02 | 3.19x |
| 2025-12-01 | 3.29x |
| 2025-11-28 | 3.32x |
| 2025-11-26 | 3.36x |
| 2025-11-25 | 3.49x |
| 2025-11-24 | 3.37x |
| 2025-11-21 | 3.43x |
| 2025-11-20 | 3.26x |
| 2025-11-19 | 3.21x |
| 2025-11-18 | 3.17x |
| 2025-11-17 | 3.16x |
| 2025-11-14 | 3.03x |
| 2025-11-13 | 3.08x |
| 2025-11-12 | 3.07x |
| 2025-11-11 | 2.98x |
| 2025-11-10 | 2.91x |
| 2025-11-07 | 2.95x |
| 2025-11-06 | 2.86x |
| 2025-11-05 | 2.81x |
| 2025-11-04 | 2.76x |
| 2025-11-03 | 2.68x |
| 2025-10-31 | 2.70x |
| 2025-10-30 | 2.65x |
| 2025-10-29 | 2.71x |
| 2025-10-28 | 2.68x |
| 2025-10-27 | 2.38x |
| 2025-10-24 | 2.42x |
| 2025-10-23 | 2.42x |
| 2025-10-22 | 2.46x |
| 2025-10-21 | 2.49x |
| 2025-10-20 | 2.47x |
| 2025-10-17 | 2.41x |
| 2025-10-16 | 2.43x |
| 2025-10-15 | 2.39x |
| 2025-10-14 | 2.40x |
| 2025-10-13 | 2.39x |
| 2025-10-10 | 2.39x |
| 2025-10-09 | 2.43x |
| 2025-10-08 | 2.46x |
| 2025-10-07 | 2.48x |
| 2025-10-06 | 2.49x |
| 2025-10-03 | 2.51x |
| 2025-10-02 | 2.55x |
| 2025-10-01 | 2.56x |
| 2025-09-30 | 2.60x |
| 2025-09-29 | 2.60x |
| 2025-09-26 | 2.69x |
| 2025-09-25 | 2.78x |
| 2025-09-24 | 2.89x |
| 2025-09-23 | 2.91x |
| 2025-09-22 | 3.00x |
| 2025-09-19 | 2.93x |
| 2025-09-18 | 3.11x |
| 2025-09-17 | 3.11x |
| 2025-09-16 | 3.13x |
| 2025-09-15 | 3.16x |
| 2025-09-12 | 3.12x |
| 2025-09-11 | 3.16x |
| 2025-09-10 | 3.11x |
| 2025-09-09 | 3.15x |
| 2025-09-08 | 3.08x |
| 2025-09-05 | 3.03x |
| 2025-09-04 | 2.96x |
| 2025-09-03 | 2.92x |
| 2025-09-02 | 2.97x |
| 2025-08-29 | 2.91x |
| 2025-08-28 | 2.91x |
| 2025-08-27 | 3.04x |
| 2025-08-26 | 3.02x |
| 2025-08-25 | 3.00x |
| 2025-08-22 | 3.02x |
| 2025-08-21 | 2.88x |
| 2025-08-20 | 3.08x |
| 2025-08-19 | 3.15x |
| 2025-08-18 | 3.04x |
| 2025-08-15 | 3.01x |
| 2025-08-14 | 2.96x |
| 2025-08-13 | 3.05x |
| 2025-08-12 | 3.05x |
| 2025-08-11 | 2.98x |
| 2025-08-08 | 2.98x |
| 2025-08-07 | 2.83x |
| 2025-08-06 | 2.75x |
| 2025-08-05 | 2.69x |
| 2025-08-04 | 2.66x |
| 2025-08-01 | 2.49x |
| 2025-07-31 | 2.48x |
| 2025-07-30 | 2.50x |
| 2025-07-29 | 2.60x |
| 2025-07-28 | 2.71x |
| 2025-07-25 | 2.70x |
| 2025-07-24 | 2.74x |
| 2025-07-23 | 2.84x |
| 2025-07-22 | 2.75x |
| 2025-07-21 | 2.73x |
| 2025-07-18 | 2.76x |
| 2025-07-17 | 2.87x |
| 2025-07-16 | 2.87x |
| 2025-07-15 | 2.90x |
| 2025-07-14 | 2.94x |
| 2025-07-11 | 3.04x |
| 2025-07-10 | 3.09x |
| 2025-07-09 | 3.17x |
| 2025-07-08 | 3.19x |
| 2025-07-07 | 3.12x |
| 2025-07-03 | 3.21x |
| 2025-07-02 | 3.13x |
| 2025-07-01 | 3.15x |
| 2025-06-30 | 3.18x |
| 2025-06-27 | 3.15x |
| 2025-06-26 | 3.08x |
| 2025-06-25 | 3.18x |
| 2025-06-24 | 3.25x |
| 2025-06-23 | 3.21x |
| 2025-06-20 | 3.13x |
| 2025-06-18 | 3.18x |
| 2025-06-17 | 3.17x |
| 2025-06-16 | 3.15x |
| 2025-06-13 | 3.05x |
Showing the most recent 260 of 3,293 data points. The chart above shows the full history.
Related Metrics
About National Research Corporation
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Trent Green